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Abstract 
Background: Declining donor funding and competing health priorities threaten the sustainability of malaria pro-
grammes. Elucidating the cost and benefits of continued investments in malaria could encourage sustained politi-
cal and financial commitments. The evidence, although available, remains disparate. This paper reviews the existing 
literature on the economic and financial cost and return of malaria control, elimination and eradication.
Methods: A review of articles that were published on or before September 2014 on the cost and benefits of malaria 
control and elimination was performed. Studies were classified based on their scope and were analysed according 
to two major categories: cost of malaria control and elimination to a health system, and cost-benefit studies. Only 
studies involving more than two control or elimination interventions were included. Outcomes of interest were 
total programmatic cost, cost per capita, and benefit-cost ratios (BCRs). All costs were converted to 2013 US$ for 
standardization.
Results: Of the 6425 articles identified, 54 studies were included in this review. Twenty-two were focused on elimina-
tion or eradication while 32 focused on intensive control. Forty-eight per cent of studies included in this review were 
published on or after 2000. Overall, the annual per capita cost of malaria control to a health system ranged from $0.11 
to $39.06 (median: $2.21) while that for malaria elimination ranged from $0.18 to $27 (median: $3.00). BCRs of invest-
ing in malaria control and elimination ranged from 2.4 to over 145.
Conclusion: Overall, investments needed for malaria control and elimination varied greatly amongst the various 
countries and contexts. In most cases, the cost of elimination was greater than the cost of control. At the same time, 
the benefits of investing in malaria greatly outweighed the costs. While the cost of elimination in most cases was 
greater than the cost of control, the benefits greatly outweighed the cost. Information from this review provides 
guidance to national malaria programmes on the cost and benefits of malaria elimination in the absence of data. 
Importantly, the review highlights the need for more robust economic analyses using standard inputs and methods 
to strengthen the evidence needed for sustained financing for malaria elimination.
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
In the past decade and a half, remarkable progress in 
malaria control has been achieved with a 37% decline in 
malaria incidence and 60% reduction in malaria deaths 
globally [1]. Almost half of the world’s nations are now 
malaria free [2] and several countries have reduced 
malaria transmission to levels low enough to allow them 
to embark on, and in many cases achieve, elimination [3].
Despite international consensus that malaria elimina-
tion leading to global eradication is a worthwhile goal 
[2], sustaining domestic and international funding as the 
malaria burden declines is a serious concern for many 
countries. External aid is on the decline [4] and multi-
lateral and bilateral donor funds are increasingly shifting 
away from disease-specific financing or being targeted 
towards low-income, high-burden countries. At the same 
time, domestically there is mounting competition for 
limited resources from other pressing disease priorities.
There is little disagreement that elimination is an 
attractive investment in the long term due to its ability to 
pay for itself through future reductions in spending and 
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its generation of broader economic benefits. The con-
tribution of malaria elimination to colossal health and 
development returns of global eradication is also implic-
itly recognized [5, 6]. Notwithstanding, malaria elimi-
nation requires additional front-loading of investments 
into robust surveillance systems to detect and respond to 
remaining cases. While socio-economic and other struc-
tural changes will eventually change the intrinsic baseline 
potential for transmission in countries such that active 
measures are no longer required [7], the decision facing 
policymakers is how to best allocate finite resources in 
the short term. Countries who have successfully lowered 
their malaria burden are faced with the risk of losing or 
severely reducing their recurrent expenditure for elimi-
nation and preventing the re-introduction of malaria at 
a critical period in the malaria elimination efforts [8]. 
At the same time, they face the risk of resurgence due to 
the persistent importation of new cases which will not 
only have devastating effects on the health and welfare 
of individuals, but will also place an additional economic 
burden on the health system. A review on malaria resur-
gence occurring from the 1930s through to the 2000s 
demonstrated that almost all resurgence events could be 
attributed, at least in part, to the weakening of malaria 
control programmes for a variety of reasons, of which 
resource constraints were the most common [9]. In addi-
tion, lessons learned from the Global Malaria Eradication 
Programme (GMEP), which ended in 1969, affirm that 
while well-funded interventions can have a major impact 
on the disease, such gains are fragile and can easily be 
reversed particularly in the short term in areas that con-
tinue to be epidemiologically and entomologically recep-
tive and vulnerable.
The economic impact of malaria has been studied for 
well over a century. The numbers of such studies have 
escalated since the conclusion of the GMEP in the late 
1960s and more so starting early 2000. Many of these 
studies have reported data on the economic burden 
of malaria and the cost of malaria programmes. How-
ever, evidence on the economics of malaria elimination 
remains disparate without a comprehensive synthesis 
of the marginal costs of elimination that can be used by 
policymakers for decision-making. Policymakers need to 
know how much it costs to achieve reductions in malaria 
burden and elimination, whether the cost savings of elim-
ination will offset the initial investment given that elimi-
nation requires to avert the last few cases, and what are 
the financial returns of elimination versus maintaining 
the status quo.
Economic methods such as cost-effectiveness analysis 
(CEA) and cost-benefit analysis (CBA) have commonly 
been used to assess the comparative value of investing 
in malaria control interventions. CEA, which calculates 
the amount of funding an intervention needs to prevent 
loss of a standard unit of disease burden, is the most 
commonly used approach to compare the economic 
attractiveness of health programmes. In an elimination 
context, CEA is relevant for identifying the optimum mix 
of interventions needed to sustain elimination. However, 
it does not help drive decisions on the economic appeal 
of malaria elimination as a whole [10]. In addition, as the 
burden of malaria diminishes, elimination interventions 
become less cost-effective because the incremental health 
gains are significantly smaller compared to programme 
costs. Furthermore, malaria transmission becomes 
increasingly concentrated in small geographic areas that 
are often difficult, and more expensive to reach such that 
a a simple cost-effectiveness ratio (CER) is unlikely to be 
favourable [11]. When evaluated as a CER, the health and 
economic gains associated with elimination may already 
be captured by control [12]. Lastly, CERs may not fully 
capture all the benefits and positive externalities that 
malaria elimination and prevention of re-introduction 
(POR) may bring, particularly when considering the cost 
of malaria resurgence [9, 13].
To generate results most relevant to policy, malaria 
elimination requires a comparison of cost with a coun-
terfactual scenario of malaria control to reflect program-
matic realities. In practice, most economic analyses in 
malaria use a loosely defined status quo, which varies 
substantially but is most often that of partial control. 
WHO recommends a null state of disease without inter-
vention as the counterfactual scenario. Used in several 
analyses, this alternative is neither pragmatic nor sus-
tainable but can provide information to understand the 
benefits of continued investment in malaria when the 
disease is greatly reduced or absent. Others have recom-
mended the use of controlled low-endemic malaria as 
the most policy-relevant alternative for economic analy-
ses of elimination [13]. However, the threats of drug and 
insecticide resistance and the instability of international 
financing mean that malaria control may not be sus-
tained in the long term. In addition, elimination delivers 
additional indirect benefits outside of health. As a coun-
try approaches and reaches elimination, other countries 
benefit from reduced importation of malaria conferring 
positive externalities to neighbouring countries as well. A 
comprehensive CBA enables these broader benefits to be 
translated into a common metric and is therefore a more 
effective means to inform strategic decisions.
The aim of this paper is to review the existing literature 
and evidence on the costs and benefits of malaria elimi-
nation. Specifically, this paper presents a comprehensive 
review of literature on the cost of malaria control as well 
as those of achieving and of sustaining elimination and 
the benefits generated by malaria elimination compared 
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to the cost of malaria control. The review intends to elicit 
evidence along the various phases of the programme: 
control, elimination and POR [34].
Methods
Search strategy
Following PRISMA guidelines [14], a systematic search 
of peer-reviewed literature in English, French and Span-
ish, pertaining to economics of malaria, published on 
or before September 2014 was conducted. Databases 
searched were MEDLINE via PubMed, SCOPUS and 
Google Scholar using MeSH terms as well as other key-
words. The term ‘malaria’ was combined with ‘elimina-
tion’ and ‘eradication’ and the following search terms: 
‘economics’, ‘cost’, ‘cost analysis’, ‘cost allocation’, ‘cost 
apportionment’, ‘cost control’, ‘cost of illness’, ‘employer 
health costs’, ‘hospital costs’, ‘health care costs’, ‘drug costs’, 
‘direct service costs’, ‘health expenditures’, ‘financing’, and 
‘cost-benefit analysis’. A detailed list of search terms and 
corresponding results are available upon request.
Two independent database searches were carried out 
to ensure an exhaustive search of the literature. AA, who 
conducted the literature search, was blinded to the initial 
search strategy but used the same databases and publica-
tion timeframe. The two lists of papers were subsequently 
merged and duplicates were removed. Reference lists of 
papers that met the inclusion criteria were also screened 
and included 13 additional articles that were deemed 
relevant.
Article screening and selection
Titles and abstracts of all initial search results were 
reviewed for relevance, and those that included some 
form of economic analysis were assessed further for eligi-
bility. Articles that did not have abstracts available online 
but were thought to be relevant based on their titles alone 
were included in the full-text assessment. Articles were 
excluded during full-text assessment if they did not meet 
the inclusion criteria or if their full-text versions could 
not be located after multiple attempts. In case of a disa-
greement during article selection, inclusion and exclu-
sion, data extraction, article categorization and quality 
appraisal, the authors discussed each case separately until 
a consensus was reached.
Inclusion criteria
Articles were included if they: (a) evaluated at least three 
interventions, suggesting intensive control or elimina-
tion rather than individual or limited interventions; (b) 
presented final costs and benefits in economic or mon-
etary terms; and, (c) provided a clear description of data 
sources and methodology. Micro-economic studies that 
assessed the cost of delivering malaria interventions to 
the health system were included and economic evalua-
tions that included cost-benefit type analyses on malaria 
interventions were also included.
Exclusion criteria
Studies that used preference approaches (e.g., willingness 
to pay) for valuing costs and benefits were excluded as a 
way to limit the analysis to studies that used empirical 
or secondary cost data rather than elicitation methods. 
Papers that only presented descriptive statistics or reiter-
ated findings from other studies already included in the 
review were also excluded. However, any review papers 
that either conducted any primary analysis on scientific 
literature were included [10, 15].
Data abstraction, standardization and qualitative synthesis
A standard Microsoft Excel® template was used to 
abstract detailed information about each study’s pub-
lication year, study setting, study period, sources of 
data, and the outcomes of interest. Monetary data were 
first adjusted to US$ in the year of the initial study (if 
the authors had not already done so) using historical 
exchange rates provided in the article. If the article did 
not provide exchange rates, historical exchange rates 
were obtained from the World Bank official exchange 
rate database for year 1981 onwards [16] and other online 
sources such as OANDA [17]. For studies where the cur-
rency year was not provided, the publication date or date 
of article submission was used for the currency conver-
sion. All monetary data were standardized to 2013 US$ 
using consumer price index conversion factors published 
by Oregon State University, USA [18].
Studies that assessed health system costs of malaria 
control and elimination were abstracted for total costs, 
cost per population at risk (PAR), and cost per capita. 
When total costs only were provided, the annual cost per 
capita was calculated by dividing the annual aggregate or 
total cost by either the PAR or total population numbers 
reported in the articles or their supplements published 
online. Similarly, the authors attempted to convert other 
averaged costs (e.g., cost per person protected, cost per 
suspected case, cost per case treated) into cost per cap-
ita whenever possible to help account for differences in 
intended programme coverage. It is important to note, 
however, that a standardized way to measure or calculate 
PAR does not exist [19–21] making comparisons among 
such reported costs potentially problematic.
For CBAs, net benefits (also referred to as net present 
value or net social benefit) and benefit-cost ratios (BCRs) 
were extracted. If net benefits or BCRs were not calcu-
lated in the original study, they were computed based on 
total benefits and total costs reported in the study when-
ever possible to facilitate comparisons among CBAs.
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Quality assessment and critical appraisal
The quality of the included studies was assessed using 
two checklists published in the literature. For CBAs, the 
ten-point Drummond checklist first developed by Drum-
mond and colleagues in 1997 [22, 23] was adapted. Each 
study was assigned a total score equal to the number of 
‘yes’ ratings it received out of ten questions in the check-
list. For cost analysis studies, the two-point evaluation 
criteria developed by Fukuda and Imanaka was adapted 
to assess the quality and transparency of costing exercises 
[24]. The Fukuda and Imanaka criteria evaluated each 
costing study based on its clarity of scope and accuracy 
of costing methodology, with activity-based microcosting 
getting the highest score.
Results
Literature search
A total of 6425 articles were identified through database 
searches. After removal of duplicates, 5505 titles and 
abstracts were initially screened, and 390 full-text articles 
were reviewed further for eligibility. After reviewing full-
text articles, 40 from the database searches and 14 from 
citation snowballing were included in the final qualita-
tive analysis (Fig. 1). Most of the studies conducted more 
than one type of economic analysis and therefore are not 
classified into mutually exclusive categories.
Of the 54 articles in this review, 22 were focused on 
elimination while the remaining 32 were on intensive 
control. Fifty-three studies estimated the programmatic 
costs of malaria control and elimination, and ten studies 
estimated both costs and benefits (Table 1).
Cost to the health system
Among the 53 studies that reported the cost of malaria 
on health systems, 32 were on the cost of control 
(Table 2; Additional file 1: Table S1) and 21 on elimina-
tion and eradication (Table  3; Additional file  1: Table 
S1). These studies reported direct costs associated with 
a entire malaria programme or a set of control and elimi-
nation interventions. The earliest study was published in 
1903, with about 47% of studies being published on or 
after 2000. Seven studies looked at the costs of malaria 
control and elimination during the GMEP era (1955–
1969). More than half (27) of the studies were on Asian 
countries, such as India, Sri Lanka and Thailand, and a 
number of states in western Asia. Eight studies were in 
African countries, while another 12 had a global, regional 
or multi-country focus. Five studies were in South Amer-
ican countries and only one was in Europe. Overall, pro-
grammatic costs varied immensely from a few hundred 
dollars to a several hundred million, owing to heteroge-
neity in study setting or geographic reach, study period, 
mix and scale of interventions, and costing methodology, 
among others. Tables 2 and 3 summarize the findings by 
country, region, focus (malaria control and elimination), 
and study period.
Health system costs of malaria control
Of the 32 studies on costs of malaria control, only 24 
(45%) used empirical data such as public and private 
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Fig. 1 PRISMA diagram
Table 1 Summary of included articles
Total number of studies included in  
qualitative review
54
Number of studies with more than one 
economic outcome reported
9
Total number Per cent (%)
Type of study
 Cost to health systems 53 98.1
 Cost-benefit analyses 10 18.5
Focus of study
 Elimination 22 40.7
 Control 32 59.3
Publication date
 On or after 2000 26 48.1
 Before 2000 28 51.9
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Table 2 Cost of malaria control to the health system
a Unless otherwise stated, the costs reported here are costs per capita, computed by dividing total program costs by the total population in the area of 
implementation
b These costs represent the costs for detecting and treating cases and may not include prevention costs
c These costs reflect the cost of selected interventions and not the entire programme
Country or region Study period Cost per capita (2013 US$)a Cost per PAR (2013 US$) Source
Global 2006–2015 2.50 Not provided [25]
2003–2009 Not provided 1.42–11.13 [26]
2002–2007 Not provided 0.47–0.80 [27]
Africa
 Ethiopia 2011–2015 1.67 2.94 [28]
 Kenya 1990 0.28 Not provided [29]
 Liberia 1953–1961 31.25–39.06 Not provided [30]
 Mauritius 10-year time horizon 2.37 2.37 [13]
 Rwanda 2011–2015 4.76 6.64 [28]
 Senegal 2011–2015 4.26 4.26 [28]
 Sub-Saharan Africa 2003 1.21–2.22 1.76–2.61 [31]
2006–2015 3.47 4.65 [32]
 Swaziland 10-year time horizon 0.94 4.88 [13]
 Tanzania 2011–2015 2.14–2.21 2.14–2.21 [28]
10-year time horizon 3.26 3.26 [13]
2011–2015 2.87 2.87 [28]
 Zambia 1929–1949 11.86 Not provided [33]
Americas
 Brazil 1989–1996 2.15 6.60 [34]
 Colombia 1993–1998 0.54–3.48 Not provided [35]
Asia
 Afghanistan 1953 1.34 Not provided [36]
 Bangladesh 2008–2012 Not provided 0.40 [37]
1990 Not provided 0.02 [38]
 China 10-year time horizon 0.12–0.21 0.16–0.22 [13]
 India 1953 0.30 Not provided [36]
1990 Not provided 0.12 [38]
1953–1977 0.36 Not provided [39]
1989 9.39 Not provided [40]
 Indonesia 1990 Not provided 2.16 [38]
 Nepal 1990 Not provided 0.52 [38]
Unspecified 0.11–1.21 Not provided [41]
1984–1985 0.45–1.36 Not provided [42]
 Palestine 1921–1922 19–32 Not provided [43]
 Sri Lanka 2009 Not provided 1.95 [44]
2004 Not provided 0.87–2.06 [44]
1994–1995 Not provided 0.36–4.26 per person protectedc [45]
1977–1981 1.71 Not provided [46]
1953 0.80 Not provided [36]
1934–1955 0.63–5.22 Not provided [47]
 Thailand 1995 Not provided 12.94–15.40 per caseb [48]
1990 Not provided 1.59 [38]
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expenditure reports or survey data. Eight studies used 
historical expenditures and budgets to extrapolate the 
costs of intensive control in Africa [28, 31, 32, 61], India 
[62], Thailand [48], Nepal [41], and globally using varying 
time periods [63].
The median annual cost per capita for malaria control 
across all studies was $2.21 (range $0.11–$234.17). Sabot 
et  al. (China), Some et  al. (Kenya), Ramaiah (India), and 
Haque et al. (Bangladesh) reported some of the lowest per 
capita costs at $0.12–$0.21, $0.28, $0.36, and $0.40, respec-
tively (Table 2; Fig. 2) [13, 29, 37, 39]. Two studies by Mills 
showed comparatively low per capita costs for malaria con-
trol in Nepal across several districts, ranging $0.11–$1.36 
[41, 42]. Control costs ranged from $0.11 in Nepal [38] to 
$9.39 in India [40], $32 in Palestine [43] to $39.06 in Liberia 
[30]. In Nepal and India, the costs included interventions 
such as testing and treatment, indoor residual spraying 
(IRS), and bed nets, while in Palestine and Liberia they 
included community education, environmental manage-
ment and chemoprophylaxis. Costs also varied within 
countries over time, partly due to the mix of interventions 
that were included in the costing. For example, in India, 
Table 3 Cost of malaria elimination to the health system
a Unless otherwise stated, the costs reported here are costs per capita, computed by dividing total program costs by the total population in the area of 
implementation
b These costs represent the costs for detecting and treating cases and may not include prevention costs
c These costs reflect the cost of selected interventions and not the entire programme
Country or region Study period Cost per capita  
(2013 US$)a
Cost per PAR  
(2013 US$)
Source
Africa
 Mauritius 10-year time horizon 4.63 4.63 [13]
1955–2008 3.03–6.22 Not provided [49]
 São Tomé and Principe 2007 (modeled over 20 years) 12 Not provided [50]
 Swaziland 2007 (modeled over 20 years) 3.00 Not provided [50]
10-year time horizon 2.65 13.77 [13]
 Tanzania 10-year time horizon 4.22 4.22 [13]
Americas
 Mexico 1971–1976 0.18 Not provided [51]
1970 0.54 Not provided [52]
Asia
 China 1994–1995 1.23 per suspected caseb 0.05 [53]
2007 (modeled over 20 years) 0.27 2 [50]
2007 (modeled over 20 years) 0.27 2.17 [54]
10-year time horizon 0.23–0.54 0.30–0.55 [13]
 India Unspecified Not provided 0.58 per person protected [10]
 Indonesia Unspecified Not provided 0.97 per person protected [10]
 Iran Unspecified 20.95 Not provided [55]
 Iraq 1964–1970 2.96 Not provided [56]
 Jordan 1964–1970 0.95 Not provided [56]
 Lebanon 1964–1970 1.68 Not provided [56]
 Philippines 1998–2010 Not provided 0.67–13.08 [57]
 Solomon Islands 2008 1.60 Not provided [58]
2007 (modeled over 20 years) 20 Not provided [50]
 Sri Lanka 2007 (modeled over 20 years) 1.00 Not provided [50]
Unspecified Not provided 0.86 per person protectedc [10]
 Syria 1964–1970 0.73 Not provided [56]
 Taiwan Unspecified Not provided 0.52 per person protectedc [10]
1952–1957 15.06 Not provided [59]
 Thailand Unspecified Not provided 1.54 per person protectedc [10]
 Vanuatu 2008 3.34 Not provided [58]
2007 (modeled over 20 years) 27 Not provided [50]
1991 18.44 Not provided [60]
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control costs were reported at $0.36–$0.58 during the 
GMEP era. Costs were generally lower in Asia compared to 
Africa.
In a sub-set of 13 studies conducted after 2000, of which 
only ten were conducted in Africa, control costs ranged 
from $0.94 in Swaziland and $4.75 per capita in Rwanda 
(median $2.30 per capita). In Asia costs ranged from 0.40 
per capita in Bangladesh and $2.06 per capita in Sri Lanka 
(median $0.64). Most of these studies did not use the full 
package of WHO recommendations for malaria control at 
scale. None of the studies in the Americas has been con-
ducted since 2000.
Stuckey et al. [61] modelled the cost of implementing 
distribution of long-lasting insecticidal nets (LLINs), 
IRS, and intermittent screening and treatment among 
school children twice per year at 80–90% coverage in 
Nyanza Province of western Kenya at $179.50–$234.17 
annually per capita. However, these costs were based on 
modelled coverage of interventions rather than actual 
scales.
With respect to cost per PAR, the overall median 
cost per PAR for malaria control, across all studies was 
$2.15 (range $0.02–$11.13). Kondrashin reported the 
lowest cost per PAR at $0.02 in Bangladesh, followed 
by $0.12 in India and $0.52 in Nepal (Fig. 2) [38]. Snow 
et al. [27] also reported low cost per PAR ($0.47–$0.80) 
for Plasmodium falciparum infections across 87 coun-
tries. These two studies used aggregated budget data 
from WHO, Global Fund and the World Bank. Only two 
studies that used empirical data reported cost per PAR, 
which ranged from $0.87 to $1.95 in Sri Lanka [44] and 
$6.64 in Rwanda [28].
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Health system costs of malaria elimination
Analyses of actual expenditures for programmes that 
have recently or are currently eliminating malaria have 
been conducted in only a few selected places, primar-
ily in Asia and Africa with some work in South America 
and Europe (Table 2; Additional file 1: Table S1). Of the 
21 studies on costs of malaria elimination with known 
data sources, only 11 used empirical data. Eight of the 21 
studies looked at the prospective costs of elimination and 
eradication while the rest used retrospective costs.
Total programmatic costs of malaria elimination ranged 
from $10,472 in Iran per 500 population (or $20.95 per 
capita) [55] to $27 million per year in South Africa [64] 
(or $ 0.52 per capita) (Additional file  1: Table S1). The 
median annual cost per capita for malaria elimination 
across all studies was $3.00 (range $0.10–$20.95) In Iran 
the assumptions for each type of intervention included 
were not uniform. Larviciding and IRS were implemented 
annually, however it is unclear if the costs for insecticide-
treated nets (ITNs) and treatment were yearly. In terms 
of cost per capita, the range of reported costs was $0.18 
in Mexico in 1971 [51] to $0.27 in China [76], $15.06 in 
Taiwan [59], $20.95 in Iran [84], and $27 in Vanuatu 
[50] (Table 2; Fig. 3). A study in the Aneityum Island of 
Vanuatu reported the second highest cost per capita at 
$18.44 [60]. This 1991 campaign included weekly mass 
drug administration (MDA), ITN distribution, and the 
use of larvivorous fish in breeding sites and was success-
ful in ending local transmission. Barring a few exceptions, 
reported elimination costs per capita were generally low-
est in the Asian countries (i.e., China [13, 50, 53, 54], India 
[10], Indonesia [10], Philippines [57], Taiwan [10], Thai-
land [10], Sri Lanka [50], and Vanuatu [58]) and Mexico 
[51, 52]. Costs were generally highest in African nations, 
such as Mauritius [49], São Tomé and Principe [50], Swa-
ziland [13, 50], and Tanzania (Zanzibar) [13].
Assessing a sub-set of 12 studies carried out after 2000, 
five were carried out in Africa, eight in Asia including 
one carried out in the Philippines between 1998 and 2010 
and six with unspecified dates. In the eight studies car-
ried out in the Asia Pacific, costs ranged from $0.27 per 
capita in China to $27 in Vanuatu (median $1.30). Elimi-
nation costs were higher in Africa, with costs ranged 
from $2.65 in Swaziland to $4.22 in Tanzania and $12 in 
Sao Tome (median $4.22 per capita).
In terms of cost per PAR, elimination in China has the 
lowest average annual cost of $0.05 [53] (Table 2; Fig. 3). 
Similarly, modeled costs per PAR for elimination in 
China were $0.30 in Jiangsu and $0.50 in Hainan, while 
POR is estimated to be $0.13 per PAR in both provinces 
[13]. Other countries report much higher cost per PAR. 
For example, the cost of Mauritius’s second elimination 
campaign in 1975–1990 was approximately $4.63 per 
PAR per year, even though several economic costs and 
contributions by external partners were not included [9, 
49]. Costs per PAR in different provinces in the Philip-
pines ranged from $2.77 to $4.33 (excluding outbreak 
years) [57]. Four countries in the Middle East reported 
similar costs per PAR in 1970 ranging from $0.73 to $2.96 
[56].
Economic benefits
Several studies explored the other economic benefits of 
investing in malaria control and elimination without a 
cost component. Two studies found that a reduction in 
malaria burden was associated with increased house-
hold spending in India [65] and increased household 
consumption in Vietnam [66]. In the USA and Latin 
American countries, exposure to malaria elimination 
programmes was associated with less work disability 
[67] and higher incomes [68] in adulthood. In a widely 
cited study, Gallup et al. [69] found that a 10% reduction 
in malaria burden was associated with as much as 0.3% 
in gross domestic product (GDP) growth. Finally, Hong 
found that between 1850 and 1860 in the USA, people 
who migrated from one area to another place with less 
malaria accumulated greater real estate wealth compared 
to those who relocated to a more malarious area [70].
Cost‑benefit analyses
Of the ten CBAs identified (Table 4; Additional file 2: Table 
S2), three were conducted during the GMEP era [39, 71, 
72] and five were on malaria elimination. Eight were origi-
nal studies while two articles were reviews with overlap-
ping studies included [10, 15] and only two used empirical 
data [39, 72]. The main type of economic benefit identified 
in the studies was increased labour productivity due to 
reductions  in morbidity and absenteeism. Other benefits 
included reductions in treatment costs and gains from the 
migration of labour into previously malarial areas.
All but one study in Zambia [33] showed a positive 
BCR, with BCRs for control ranging from 2.4 in the Phil-
ippines [10], 4.14 and 9.22 in India [39, 75] and 17.09 in 
Greece [74], to over almost 150 for elimination in Sri 
Lanka [15] (Table 3).
Quality assessment and critical appraisal
The results of the quality assessment of CBAs using the 
Drummond ten-point checklist are in Additional file  3: 
Table S3. Out of a possible ten points, the average score 
for CBAs was 4.8 (range 0–9). Several CBA studies 
scored poorly for failing to discount future benefits, iden-
tify alternative scenarios and conduct incremental analy-
ses, carry out sensitivity analyses, and address key issues 
related to resource allocation in the country or setting 
where the study was situated. Additional file 4: Table S4 
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Table 4 Cost-benefit analyses
a Calculated by authors based on reported benefits and costs
Country or setting Study period Focus (control  
or elimination)
Benefit‑cost ratio Source Quality assessment 
score (out of 10)
Global 2010–2030 Elimination 6.11 [73] 7
Greece 1946–1949 Elimination 17.09a [74] 1
India 1953–1954, 1976–1977 Control 9.27 [39] 6
2000–2001 Control 4.14a [75] 3
Iraq 1958–1967 Elimination 6.3a [71] 3
Paraguay 1965 Elimination 2.6–3.3 [72] 3
Philippines Unspecified Control 2.4 [15] NA
Sri Lanka 1947–1955 Control 146.3 [15] NA
Sub-Saharan Africa Varies by study Control 1.9–17.1 [10] NA
Sudan 1977–1984 Control 4.6 [15] NA
Thailand Unspecified Control 6.5 [15] NA
West Pakistan 1960 Control 4.9 [15] NA
Zambia 1929–1949 Control 0.57a [33] 9
2006–2015 Control 40 [28] 6
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shows the results of quality evaluation of the cost studies. 
Over half of studies that evaluated programmatic costs 
described their cost inputs and thus scored high on the 
scope of costing metric of the Fukuda and Imanaka crite-
ria. Although a total of 54 studies were evaluated in this 
review, strong conclusions cannot be drawn and the find-
ings should be interpreted with caution.
Discussion
Summarizing evidence on economics of malaria from het-
erogeneous studies, sources, inputs, methods, time, and 
geography is challenging. While total costs were corrected 
for population size by presenting them as cost per capita 
or cost per PAR, other factors contributed to the magni-
tude of the costs. The methodologies and cost inputs used 
were not standard and many studies used secondary data. 
In some cases, the cost inputs, cost categories, interven-
tions, and assumptions that were included were not stated 
explicitly. Some studies provided coverage inputs, such as 
total population or PAR, while others presented a simple 
total programmatic cost. Among the studies included in 
the review, discount rates when specified, ranged from 3 
to 16%. Many of the studies included used a public sector 
perspective for economic analysis. However, these costs 
represent only part of the equation. While most malaria 
control efforts are largely government-led public health 
initiatives, programmatic costs are only part of the picture 
as individuals, households and employers from the pri-
vate sector may also incur costs for malaria treatment and 
prevention. It is unclear to what extent these direct and 
indirect costs were included in the literature examined. 
Out-of-pocket expenditures for treatment as well as trans-
port to health facilities, as well as any indirect opportunity 
cost of lost wages and absenteeism, may have substantial 
consequences. Other studies have shown that up to 6% of 
a household’s total spending on health, even when public 
sector primary health care is free and indirect costs can 
translate to $150 in lost earnings per malaria episode [76].
Numerous caveats with respect to the relevance and 
extrapolation of the results exist and findings should be 
used cautiously. First, programme costs depend largely 
on the mix and scale of interventions, which differ from 
country to country, or even among districts or provinces 
in countries with decentralized systems. Mauritius, for 
example, employs a more costly border-screening pro-
gramme for visitors from malaria-endemic countries. 
Some earlier studies did not incorporate post-elimination 
costs of surveillance and other interventions to prevent 
re-introduction of the disease, as the expectation at the 
time was that malaria-related expenditure would stop after 
elimination. In the early studies that did actually demon-
strate reductions in post-elimination expenditures, the 
value of these savings were diminished due to discounting, 
preventing them from fully offsetting the initial increased 
investments to reach elimination. Second, cost is affected 
by the size and programme efficiency of a health system 
used to implement interventions, as well as the cover-
age rates employed. Smaller countries such as Swaziland 
potentially due diseconomies of scale appear to have 
higher costs. Sri Lanka on the other hand, has one of the 
earliest and effective public health systems with generally 
low levels of health expenditures. Costs also differed by the 
region (Africa or Asia) with costs in Asia much lower than 
in Africa, possibly due to higher use of vector control in 
Africa, as well as size and development status of the coun-
try evaluated. Fourth, timing plays an important role in 
determining the price of consumables, services and labour. 
Estimates from earlier years were generally lower than 
that from the contemporary studies due to the difference 
between the relative prices of physical and human inputs 
to malaria control. In addition, the current menu of tools 
and interventions for malaria is broader and more costly, 
encompassing LLINs, intermittent preventive therapy for 
pregnant women and children, artemisinin-combination 
therapy, and rapid diagnostic tests, as well as innova-
tive delivery models. Lastly, there are wide variations in 
regional, epidemiological and economic contexts. The 
presence of the more tenacious Plasmodium vivax could 
have substantial cost implications during the elimination 
phase. Barring a few studies based on mathematical mod-
els, few measured the cost of the full spectrum of WHO 
recommendations for the control of malaria. For elimina-
tion, there is currently no recommended optimal package 
as the interventions are often context specific and tailored 
to the particular landscape of the country. While some 
of these programmatic, temporal, spatial, and methodo-
logical differences are expected in costing studies, future 
studies should attempt to standardize methodologies to 
facilitate meaningful comparisons of cost estimates.
Despite the challenges in directly comparing costs 
in the studies reviewed, some trends can be observed. 
While the investment needed to achieve elimination var-
ied greatly between countries and contexts, it is likely 
that the immediate costs for elimination will initially be 
equal to, or higher than those of a control programme, 
as indicated by data from Swaziland [13], due to initial 
investments in programme re-orientation to strengthen 
surveillance systems. This cost however tend to decrease 
as the focus progresses to the POR phase [42–44] due 
to streamlining of surveillance activities, reductions in 
commodity expenditures and in some cases, integration 
of supporting health system activities [13, 77]. Two stud-
ies that collected empirical data on actual expenditures 
over multiple programmatic phases support this claim. In 
Sri Lanka, expenditures per PAR declined when moving 
from a high level of control to controlled low-endemic 
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malaria [44]. In the Philippines declining marginal expen-
ditures were observed from control to POR, where costs 
per PAR were more than halved [57]. Similar findings 
have been reported in three Namibian regions in a recent 
study published after the initial search was conducted 
[78]. In contrast, Ruberu’s analysis in Sri Lanka suggested 
that the high short-term cost of elimination is exceeded 
by long-term investments in control and the resulting 
consequences of productivity losses [46]. This is sup-
ported by the Eighth Report of the Expert Committee on 
Malaria which suggested that the cost of a well-operated 
programme to consolidate and sustain elimination would 
be only 65–75% that of operating an ‘all-out’ or intensive 
malaria control programme [79].
The bulk of the CBAs dated from the GMEP era. Sev-
eral of these studies focused on periods of relatively high 
transmission (i.e., control), even though elimination or 
eradication was mentioned in the title or body of articles, 
emphasizing the need to standardize the use of malaria 
terminology. Most of these studies were prospective in 
design and suggest that the benefits of intensive con-
trol and elimination exceed costs. However, these stud-
ies have not been followed up subsequently to assess the 
validity of their conclusions. The main type of economic 
benefit  identified in the studies was  increased labour 
productivity due to reductions  in morbidity and absen-
teeism. Other benefits included reductions in treatment 
costs and gains from the migration of labour into previ-
ously malarial areas. Factors such as school absenteeism 
due to malaria and its effect on cognitive development 
and educational outcomes have also been reported by 
several studies, for example, Lucas reported that in Sri 
Lanka ending malaria in the most heavily affected region 
led to an estimated 17% increase in literacy [80]. Simi-
larly, Bleakley et al. [81] examined the effects of malaria 
on female educational attainment in Paraguay and 
found that every 10% decrease in malaria incidence led 
to 0.1  years of additional schooling, and increased the 
chance of being literate by one to two percentage points. 
While an important factor on human capital accumula-
tion, these were not included in this review as they did 
not present costs in economic terms, an important ele-
ment in order to be comparable and used in economic 
analyses.
As with cost estimates, the heterogeneity in cost-
benefit estimates can be explained largely by the lack 
of standardization in calculating BCRs, particularly on 
how benefits were defined, categorized or estimated. 
Some studies used a broad definition of benefits from a 
societal perspective, while others used a narrow defini-
tion of outputs. Some studies also made wide-ranging 
assumptions about the effect of malaria on labour, tour-
ism and the larger economy and attempted to include 
their effect into their metric. The studies also use varying 
time periods of analysis and a variety of discount rates 
ranging from 3 to 10% to obtain present values. A com-
plete economic assessment of elimination should include 
direct and indirect benefits, some of which are difficult 
to measure. The economics of malaria elimination are 
complicated because most of the benefits of elimination 
are typically realized only when an absolute threshold 
of malaria-free status is achieved, by conferring indirect 
benefits such as economic development [82]. While it is 
expected that one of the benefits of malaria is likely to be 
a positive effect on tourism, two studies carried out in an 
area of South Africa and Mauritius [83, 84] reported that 
tourists’ perceptions of risk were highly unresponsive to 
actual changes in malaria transmission. A comprehen-
sive CBA should compare the potential net benefits of 
elimination with those of control. Ideally, such as exercise 
should begin with cost-minimization analysis to estab-
lish the optimum package of interventions with which to 
achieve control and elimination. Nevertheless, the overall 
favourable BCR of investing in malaria supports the case 
for continued investment in malaria elimination within 
individual countries and globally.
Few studies have looked at the relative returns to elimi-
nation versus long-term control. The Eighth Report of the 
Expert Committee on Malaria (1961) suggested that expe-
rience indicated that a well-operated consolidation mech-
anism costs per annum 65–75% of an attack mechanism 
[79], and there is some evidence that the costs for elimi-
nation are likely to be equal to or higher than those of a 
control programme [50, 85]. Indeed, one of the strongest 
arguments against elimination is the increasing cost asso-
ciated with finding and treating decreasing numbers of 
cases, since the final few cases require an enormous out-
lay of resources that may be considered disproportionate 
to the marginal return [86]. This discussion around the 
financing of malaria elimination is no different to that of 
other elimination and eradications programmes. Since 
the start of the Global Polio Eradication Initiative (GPEI), 
the burden has been reduced by over 99%. Twenty-seven 
cases of wild polio have been diagnosed this year, all in 
Afghanistan, Pakistan and Nigeria. Finishing the job of 
eradicating polio will cost an additional $1.5 billion to 
enhance vaccination and surveillance efforts in hard-
to-reach places. This translates into a cost of about $0.5 
billion a year or $18 million per case averted. However, 
eradicating polio will have saved at least $40–50 billion 
between 1988 and 2035. In the USA alone, eradicating 
polio is estimated to have saved about $220 billion since 
1955. Nevertheless, some public health advocates con-
tinue to question whether polio should be merely man-
aged rather than eliminated and the money be allocated 
to fighting other diseases. However, withdrawing support 
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will have devastating health, social and economic effects. 
In 2003, certain states in Nigeria briefly stopped deliv-
ering vaccines in 2003 and as a result, GPEI spent $220 
million dealing with the resultant outbreak. Equatorial 
Guinea also recently saw its first reported polio case since 
1999, when a virus from Cameroon exploited a drop in 
the routine vaccination of children [87, 88].
Similarly, while the literature supports the claim that 
investment in malaria elimination provides generous 
benefits, the challenge is sustaining financial support. 
Donor funding is on the decline in favour of programmes 
with seemingly greater potential impact on mortality 
and morbidly. Although many of the countries currently 
attempting to eliminate malaria are middle-income coun-
tries and will eventually be able to fund their programmes 
domestically, they are faced with competing priorities for 
finite amounts of financing. In addition, the long-term 
nature of elimination programmes contrasts with gov-
ernments’ and donors’ typical short-term funding cycles 
and goals. As a result, elimination programmes become 
victims of their own success and risk the withdrawal of 
funding at a critical time in their malaria epidemiology.
The review identified several gaps in the literature on the 
economics of malaria elimination. Firstly, there is no stand-
ard methodology or guidance for computing the cost of 
malaria control and elimination. The studies in this review 
employed a wide range of inputs to compute the cost of 
malaria control and elimination to arrive at the costs, mak-
ing meaningful comparisons difficult. For elimination, 
this standardization needs to include the cost likely to be 
incurred in a post-elimination scenario to allow appropri-
ate budgeting and planning. Secondly, while comprehen-
sive WHO guidance exists on interventions for the control 
of malaria, there is little direction on the epidemiological 
and economic efficiencies of various mixes of interven-
tions utilized for malaria elimination. The start-up costs of 
malaria elimination, particularly the cost of strengthening 
surveillance systems for enhanced case identification are 
also largely unknown. A country embarking on elimina-
tion will need to plan for the additional resources needed 
in its transition from control to elimination. Most of the 
studies in this review used financial costs and therefore, 
the true cost of the human resources and programmatic 
management and health system strengthening are largely 
unknown. Lastly, malaria elimination confers several 
non-health benefits to the economy. Methods to compre-
hensively quantify these benefits will greatly enable stake-
holders to strengthen the elimination argument.
Conclusion
The evidence documented in this review is important 
in answering key questions on resource allocation and 
financial planning by malaria programme managers and 
policymakers serving as an interim guide for countries 
until they are able to undertake more robust economic 
analyses in their own contexts. The investment needed 
to achieve elimination is likely to initially be equal to or 
higher than that of a control programme, particularly 
in the short term. As with any disease elimination pro-
gramme, the cost of ‘finishing the job’ is likely to be higher 
than merely controlling the disease. This higher cost must 
be built into programme budgets with appropriate advo-
cacy actions to ensure that financing is maintained well 
after elimination is achieved. At the same time, it should be 
tacit that, the total benefits of elimination, many immeas-
urable, vastly outweigh its cost. Nevertheless, there is a 
need for thorough research into the comprehensive ben-
efits of elimination to guide relevant policy decisions. At 
the same time, malaria-related expenditure is not likely to 
stop as soon as elimination is achieved. Malaria interven-
tions need to be viewed as a continuous expenditure even 
when the disease is absent, such as with routine immuni-
zation, until global eradication is achieved. Elucidating the 
health and economic costs and comprehensive benefits of 
continuing spending will facilitate such a policy shift.
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